Abstract
Medulloblastomas (MBs) of Groups 3 and 4 are malignant tumors of embryonic origin. Unfortunately, to date, these molecular groups are scarce in the characterization of new biomarkers for therapeutic purposes, which reflects a worse prognosis of the disease and an increase in relapses. In light of the above, we draw attention to the USP2 gene, a putative effector of cross-talks between the…